Home > A. Molecular pathology > Targeted therapy > Small molecules > carfilzomib
carfilzomib
Tuesday 5 July 2016
Kyprolis CFZ
| WP |
Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor . Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.
The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as lenalidomide) and have demonstrated disease progression on or within 60 days of completion of the last therapy.
See also
proteasome inhibitors
small molecules
